Compare

Zealand Pharma A/S/DKr ZEAL

1D1W1M3M6MYTD1Y5YMAX

About Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark, specializing in the discovery and development of peptide-based medicines. The company focuses on developing treatments for gastrointestinal and metabolic diseases, including obesity and diabetes. Its product portfolio includes innovative solutions like dasiglucagon, intended for severe hypoglycemia. Founded in 1998, Zealand Pharma leverages proprietary peptide platforms to address unmet medical needs. The company's strategic positioning involves strong partnerships and collaborations with pharmaceutical companies to advance its products through various stages of clinical development.
Ticker
DKr ZEAL
Sector
Health
Primary listing
CSE
Employees
578
Headquarters
Søborg, Denmark
Website
www.zealandpharma.com

ZEAL Metrics

BasicAdvanced
kr 16B
6.08
kr 38.53
0.59
-

What the Analysts think about ZEAL

Analyst ratings (Buy, Hold, Sell) for Zealand Pharma A/S stock.
Analyst projections of the future price of Zealand Pharma A/S stock.

Bulls say / Bears say

In people with obesity or overweight and type 2 diabetes, petrelintide cut average body weight by up to 9.2% after 28 weeks, against 2.0% for placebo, and improved HbA1c. The result supports its potential in a patient group with both weight and blood-sugar needs. (Zealand Pharma)
Petrelintide may stand out on treatment tolerability: only 1.9% of treated participants stopped ZUPREME-2 because of gastrointestinal side effects, close to the 1.7% on placebo. Most reported effects were mild, which could help patients stay on long-term treatment. (Zealand Pharma)
Roche and Zealand have begun three Phase 3 trials of petrelintide, targeting about 7,000 participants across obesity populations with and without type 2 diabetes and with cardiovascular disease. This puts the lead asset into large-scale testing with a major pharmaceutical partner. (Zealand Pharma)
Zealand’s other major obesity asset, survodutide, faces a serious tolerability hurdle: roughly a quarter of patients on the highest dose stopped treatment in a Phase 3 trial, often because of gastrointestinal effects. High dropout rates could limit its commercial appeal even where weight-loss results are meaningful. (Reuters, Fierce Biotech)
Petrelintide’s efficacy may be hard to distinguish from rival obesity drugs, while its blood-sugar benefit in ZUPREME-2 looked modest by comparison: HbA1c fell by up to 0.65%, versus reported rival results of 1.3% to 2.1%. That could weaken its appeal for patients with type 2 diabetes. (Fierce Biotech)
Zealand’s earnings remain exposed to lumpy partnership payments rather than recurring product sales. H1 2026 operating cash flow was negative despite reported profit, and the company expects operating costs to rise as it funds its pipeline. (Inderes)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.

ZEAL Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

ZEAL Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing ZEAL

AllUSDEURGBP
Funds
Fund name
Fund size
DKr ZEAL weighting
iShares Healthcare Innovation£DRDR
$1.3B0.21%
iShares Healthcare Innovation€2B78
$1.2B0.21%
iShares Healthcare Innovation$HEAL
$1.3B0.21%
Xtrackers MSCI Europe Small Cap£XXSC
$3.6B0.15%
Xtrackers MSCI Europe Small Cap€DX2J
$3.6B0.15%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.